Table 1. Virological success (<400 copies/ml) at 12 months–on-treatment analysis.

				Univariate	Multivariate
				analysis	analysis
Variables	Categories	N	Rate (95% CI)	(p)	Full model (p)	Reduced model (p)
Study design	Cohort	35	85.1 [83.2–87.8]	Ref
	Trial	17	86.1 [82.3–89.8]	0.90
	Cross sectional	12	85.1 [81.3–88.9]	0.99
Beginning of enrolment	≤2005	34	84.4 [81.5–87.4]	Ref
	≥2006	30	86.3 [83.8–88.8]	0.36
End of enrolment	≤2005	11	85.6 [82.2–88.9]	Ref
	2006–2009	45	84.5 [82.2–86.9]	0.92
	≥2010	7	89.6 [84.9–94.3]	0.46
Region	Western Africa	16	81.5 [77.4–85.5]	0.11
	Eastern Africa	25	87.3 [84.8–89.8]	Ref
	Central Africa	3	85.3 [78.2–92.4]	0.99
	Southern Africa	16	86.6 [84.1–89.1]	0.99
	Several region	2	76.2 [0.48–1.00]	0.18
Type of site	Public sector	51	86.4 [84.5–88.3]	Ref	Ref	Ref
	Other	10	80.2 [73.2–87.3]	0.04	0.76	0.04
Number of sites	1	35	85.1 [81.9–88.3]	Ref
	≥2	20	85.9 [83.4–88.5]	0.76
Decentralised setting	No	39	83.9 [80.8–86.9]	Ref	Ref
	Yes	15	89.6 [85.7–93.5]	0.04	0.35
	Both	7	82.4 [78.4–86.5]	0.79	0.30
Population selected	General	44	85.9 [84.3–87.5]	Ref	Ref
	General, with FU >6 months	7	77.5 [68.9–86.1]	0.01	0.43
	Specific	7	89.0 [86.5–91.5]	0.44	0.61
VL monitoring before evaluation	No	31	85.5 [82.1–88.8]	Ref
	Yes	33	85.2 [82.7–87.6]	0.86
Tracking of LTFU patients	No	49	85.4 [83.0–87.9]	Ref
	Yes	15	85.0 [81.1–8.8]	0.85
Median age at ART initiation (years)	≤36	32	84.7 [82.4–87.0]	Ref
	>36	26	85.8 [81.4–90.2]	0.60
Proportion of women	≤65	34	86.8 [83.7–89.9]	Ref
	>65	30	83.7 [81.3–86.1}	0.14
Proportion of patients in WHO stage 3–4	≤69	25	84.4 [82.0–86.8]	Ref
	>69	18	87.9 [85.3–90.6]	0.23
Median CD4 at ART initiation (cells/mm3)	≤135	30	85.9 [84.1–87.7]	Ref
	>135	27	84.4 [79.7–89.1]	0.84
Median VL at ART initiation (log copies/mL)	≤5.2	14	81.6 [77.3–85.8]	Ref
	>5.2	22	87.5 [84.8–90.1]	0.09
Proportion of EFV exposed patients	≤40	22	82.0 [77.2–86.9]	Ref	Ref
	>40	20	87.4 [84.8–90.0]	0.04	0.99
Proportion of NVP exposed patients	≤60	23	85.2 [81.4–89.0]	Ref
	>60	19	83.1 [79.9–86.4]	0.41